Pulmonx Corp (OQ:LUNG)

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
 
See Regulatory Filings on SEC
Company Contact
Address: 700 Chesapeake Dr
REDWOOD CITY CA 94063
Tel: N/A
Website: https://pulmonx.com
IR: See website
<
Key People
Steven S. Williamson
President, Chief Executive Officer, Director
Mehul Joshi
Chief Financial Officer, Principal Financial and Chief Accounting Officer
David A. Lehman
General Counsel
Geoffrey Beran Rose
Chief Commercial Officer
   
Business Overview
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its solutions, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), is designed to treat severe emphysema patients. The StratX Platform is a cloud-based quantitative CT analysis service that offers physicians with a report that is designed for its solution, which includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation and has been validated in multiple randomized controlled clinical trials.
Financial Overview
For the three months ended 31 March 2024, Pulmonx Corp revenues increased 30% to $18.9M. Net loss decreased 13% to $13.7M. Revenues reflect United States segment increase of 38% to $12.9M, Europe, Middle-East and Africa ("EMEA") segment increase of 13% to $5.1M. Lower net loss reflects Interest income increase of 28% to $1.4M (income), Foreign Exchange Gain/LossNon-Business increase from $100K to $400K (income).
Employees: 279 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $145.07M as of Mar 31, 2024
Annual revenue (TTM): $72.99M as of Mar 31, 2024
EBITDA (TTM): -$58.52M as of Mar 31, 2024
Net annual income (TTM): -$58.73M as of Mar 31, 2024
Free cash flow (TTM): -$37.96M as of Mar 31, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 38,815,760 as of Apr 30, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.